Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness

The US Food and Drug Administration has mandated that manufacturers of GLP-1 drugs, including Ozempic and Wegovy, update their labels to include warnings about a rare eye condition called non-arteritic ischemic optic neuropathy (NAION). This condition has the potential to cause blindness. The directive applies to all weight-loss medications within this drug class. The FDA's decision aims to ensure that healthcare providers and patients are fully informed about the risks associated with these medications.